Nkarta develops engineered natural killer cell therapies for autoimmune diseases, led by its candidate NKX019. NKTX reports earnings on Tue, Nov 10, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 14 | Stifel | Maintained | Buy | |
| Aug 11 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How NKTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in NKTX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTX is in one of them and how their past NKTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NKTX in an article yet. Here's the latest on the wider market.
About Nkarta
Nkarta is a clinical stage biopharmaceutical company based in South San Francisco, California. It develops engineered natural killer cell therapies made from cells donated by healthy people and produced in advance, so they can be given to patients without waiting for a custom batch. Its lead product candidate, NKX019, targets CD19 and is being studied in autoimmune diseases such as lupus nephritis and systemic sclerosis. The company aims its therapies at people living with these conditions.
- Headquarters
- South San Francisco, CA